Is CRDL or CRON more undervalued in 2026?

CirclFi compares Cardiol Therapeutics Inc. (CRDL) and Cronos Group Inc. Common Share (CRON) using 13 institutional-grade valuation models. CRDL has a Quality of Company score of 6.4/10 while CRON scores 5.2/10.

Which is a better buy — CRDL or CRON?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRDL and CRON valuations compare?

CRDL at $1.28 and CRON at $2.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRDL vs CRON Valuation Comparison 2026 — Intrinsic Value Analysis

CRDL

Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$1.28

Last close

Models

9/13

Active

CRON

Drug Manufacturers - Specialty & Generic

Cronos Group Inc. Common Share

Quality

5.2

out of 10

Value Trap

SAFE

Price

$2.84

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CRDL Fair Value	CRDL Upside	CRON Fair Value	CRON Upside
Bayesian DCF	Intrinsic	$0.42	-67.4%	$2.91	+2.3%
Earnings Power Value	Intrinsic	—	—	$2.00	-29.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.17	-86.7%	$2.62	-7.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRDL vs CRON — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRDL vs CRON — Which Stock Is More Undervalued?

CRDL scores higher with a 6.4/10 quality rating vs CRON's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cardiol Therapeutics Inc. (CRDL) and Cronos Group Inc. Common Share (CRON) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRDL currently trades at $1.28 with a QOC of 6.4/10, while CRON trades at $2.84 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).